A systematic review of the association between fatigue and genetic polymorphisms

Wang, Tengteng; Yin, Jie; Miller, Andrew H.; Xiao, Canhua

doi:10.1016/j.bbi.2017.01.007

Cited by 57 publications

(53 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of note, human papillomavirus infection is associated with an increased incidence of head and neck cancers and also appears to influence inflammatory activity and fatigue before and during radiation therapy . Polymorphisms in cytokine genes also are associated with fatigue in patients with cancer and survivors and may serve as a predisposing risk factor …”

Section: Neuro‐immune Processes and Crfmentioning

confidence: 99%

The role of neuro‐immune interactions in cancer‐related fatigue: Biobehavioral risk factors and mechanisms

Bower

2019

Cancer

137

120

View full text Add to dashboard Cite

Fatigue is a common and distressing symptom in both patients with cancer and cancer survivors. There is substantial variation in the severity and persistence of cancer‐related fatigue that may be driven by individual differences in host factors, including characteristics that predate the cancer experience as well as responses to cancer and its treatment. This review examines biobehavioral risk factors linked to fatigue and the mechanisms through which they influence fatigue across the cancer continuum, with a focus on neuro‐immune processes. Among psychosocial risk factors, childhood adversity is a strong and consistent predictor of cancer‐related fatigue; other risk factors include history of depression, catastrophizing, lack of physical activity, and sleep disturbance, with compelling preliminary evidence for loneliness and trait anxiety. Among biologic systems, initial work suggests that alterations in immune, neuroendocrine, and neural processes are associated with fatigue. The identification of key risk factors and underlying mechanisms is critical for the development and deployment of targeted interventions to reduce the burden of fatigue in the growing population of cancer survivors. Given the multidimensional nature of fatigue, interventions that influence multiple systems may be most effective.

show abstract

Section: Neuro‐immune Processes and Crfmentioning

confidence: 99%

The role of neuro‐immune interactions in cancer‐related fatigue: Biobehavioral risk factors and mechanisms

Bower

2019

Cancer

137

120

View full text Add to dashboard Cite

show abstract

“…Fatigue also is correlated with other symptoms before treatment onset, including depressed mood and sleep disturbance, although it is unclear whether these are a cause or consequence of fatigue. Other host factors that have emerged as predictors of fatigue during and after treatment have rarely have been evaluated before treatment onset, including history of depression, childhood trauma, and genetic risk factors, particularly variants in genes involved in inflammation and immune response (eg, interleukin 1 [ IL 1 ], tumor necrosis factor A [ TNFA ], and IL 6 ) . Importantly, these host factors are present before the diagnosis of cancer, which clarifies the temporal nature of their association with fatigue.…”

Section: Introductionmentioning

confidence: 99%

Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer

Bower

Asher

Garet

et al. 2018

Cancer

View full text Add to dashboard Cite

Background Fatigue is one of the most common and disabling side effects of cancer and its treatment. Although research typically has focused on fatigue that occurs during and after treatment, patients may experience fatigue even before treatment onset. The current study was designed to identify biobehavioral risk factors associated with fatigue before adjuvant therapy in women with early‐stage breast cancer. Methods Patients with stage 0 to stage IIIA breast cancer (270 women) were recruited before the onset of adjuvant or neoadjuvant therapy with radiotherapy, chemotherapy, and/or endocrine therapy. Host factors that may influence fatigue were identified from an empirically based, biobehavioral model and assessed using self‐report questionnaires, medical record review, and blood collection (for genetic data). Fatigue was assessed by questionnaire. Linear regression analyses were used to evaluate the association between host factors and dimensions of fatigue, with general fatigue as the primary dimension of interest. Results Fatigue was elevated at the pretreatment assessment compared with published controls. Bivariate analyses identified demographic, cancer‐related, and biobehavioral correlates of fatigue. In the multivariable model, predictors of general fatigue included younger age, lower educational level, lower cancer stage, and history of childhood maltreatment (all P values <.05), with the full model accounting for approximately 18.4% of the variance in fatigue. Secondary analyses identified common and specific predictors of emotional, mental, and physical dimensions of fatigue. Conclusions Among women who have not yet initiated treatment of breast cancer, demographic and psychosocial factors are associated with elevated fatigue and could be used to identify at‐risk patients for early intervention.

show abstract

“…This is supported by the observation that specific genetic polymorphism in the regulatory pathways of immune systems, i.e. TNF-α, IL-1β, IL-4 and IL-6 genes, is associated with elevated CRF [6]. In accordance with this finding, measurements of systemic inflammation relate to fatigue levels [7].…”

Section: Fatiguementioning

confidence: 80%

Rehabilitation of Cancer Survivors with Long-Term Toxicities

Schmielau¹,

Rick

Reuß‐Borst³

et al. 2017

Oncol Res Treat

View full text Add to dashboard Cite

The prognosis of cancer patients is constantly improving, which increases the importance of securing long-term quality of life. While therapy of treatment-related disability mostly succeeds a cancer-specific treatment, physicians' awareness of simultaneous supportive therapy is rising. Early interventions such as physical exercise during chemotherapy are effective in reducing conditions such as fatigue. Specific sensorimotor training is able to improve or even prevent impairment of balance caused by neurotoxic agents. Although targeted therapies reduce the risk of side effects, combinations with established drugs have to be monitored with regard to cardiotoxicity, which is already a concern in children's cancer therapy and is now also focused on in long-term adult survivors. Improvement in diagnosis und surgical procedures have reduced impairments such as lymphedema. Furthermore, management and quality of life of breast cancer patients benefit from evidence showing that physical exercise and resistance training do not increase the risk of developing lymphedema.

show abstract

A systematic review of the association between fatigue and genetic polymorphisms

Cited by 57 publications

References 76 publications

The role of neuro‐immune interactions in cancer‐related fatigue: Biobehavioral risk factors and mechanisms

The role of neuro‐immune interactions in cancer‐related fatigue: Biobehavioral risk factors and mechanisms

Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer

Rehabilitation of Cancer Survivors with Long-Term Toxicities

Contact Info

Product

Resources

About